ALZCUR.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 15:18):

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system...

Stats
Dzisiejszy wolumen	69 811.00
Średni wolumen	76 290.00
Kapitalizacja rynkowa	180.67M
EPS	SEK0 ( 2024-04-25 )
Następna data zysków	( SEK0 ) 2024-05-02
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-3.66
ATR14	SEK0.0400 (2.06%)

Wolumen Korelacja

Długi: 0.16 (neutral)

Krótki: 0.44 (neutral)

Signal:(47.618) Neutral

AlzeCure Pharma AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AlzeCure Pharma AB (publ) Korelacja - Waluta/Towar

-0.68
( moderate negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.65
( moderate negative )

0.70
( moderate )

0.46
( neutral )

AlzeCure Pharma AB (publ) Finanse

Annual	2023
Przychody:	SEK0
Zysk brutto:	SEK-476 000 (0.00 %)
EPS:	SEK-0.560

FY	2023
Przychody:	SEK0
Zysk brutto:	SEK-476 000 (0.00 %)
EPS:	SEK-0.560

FY	2022
Przychody:	SEK0
Zysk brutto:	SEK-570 000 (0.00 %)
EPS:	SEK-1.170

FY	2021
Przychody:	SEK0.00
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-1.999

Financial Reports:

No articles found.

AlzeCure Pharma AB (publ)

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.

Aktualne aktualizacje dla AlzeCure Pharma AB (publ) [ALZCUR.ST]

Upcoming Earnings Alert